Listed

Immunovant, Inc.: Form 10-Q for the period ended Jun 30, 2021

Filed with the SEC on Aug 9, 2021 and accepted by EDGAR at Aug 9, 2021, 07:09 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2021-04-01 to 2021-06-30$18.7mus-gaap:ResearchAndDevelopmentExpense
Income tax3 months2021-04-01 to 2021-06-30−$41.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-04-01 to 2021-06-30−$30.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-04-01 to 2021-06-30−$0.31us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-04-01 to 2021-06-30−$0.31us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-04-01 to 2021-06-3097,976,982 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2021-04-01 to 2021-06-30−$21.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2021-04-01 to 2021-06-30$18.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-06-30$379.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-06-30$384.8mus-gaap:AssetsCurrent
Total assetsAt period end2021-06-30$388.0mus-gaap:Assets
Current liabilitiesAt period end2021-06-30$20.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-06-30$22.5mus-gaap:Liabilities
Shareholders' equityAt period end2021-06-30$365.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001764013-21-000079. Last ingested by Listed: Nov 13, 2026, 16:26 ET. Listed shows no prices and gives no investment advice.